Late toxicity in complete response cases after definitive chemoradiotherapy for esophageal squamous cell carcinoma

Abstract

Definitive chemoradiotherapy for ESCC is effective with substantial toxicities. Further investigation is warranted to minimize the normal tissue toxicities.

Predictive factors for pericardial effusion identified by heart dose–volume histogram analysis in oesophageal cancer patients treated with chemoradiotherapy

“…In the long-term report by Ishikura et al, 10 severe heart-related adverse events occurred in about 7.2% of cases; Kumekawa et al 18 reported 8.2% and Morota et al 19 reported 5.4%. The present study had four observed cases (2.8%) of severe heartrelated adverse events of grade 3 or higher, including pleural effusion ( Table 3).…”

“…Primary tumour and lymph nodes were defined by CT, 18 F-FDG-PET and endoscopy, as gross tumour volume primary (GTVp) and GTV node (GTVn), respectively. The clinical target volume primary was GTVp plus 2-to 3-cm superior and inferior margins.…”

Constrictive Pericarditis 5 Months after Radiation Therapy in a 62-Year-Old Woman with Esophageal Cancer

“…5,9,10 Ten articles were excluded for not meeting our definition of early CP, [6][7][8][13][14][15][16][17][18][19] and 4 others because of insufficient data. [20][21][22][23] Demographic Data and Clinical Presentations. The 5 patients ranged in age from 16 to 62 years; 3 were female.…”

Multimodal Therapies for Upper Gastrointestinal Cancers – Past, Now, and Future

“…These hospital mortality rates are obviously higher than those for esophagectomy in Japan reported from specialized centers (2%) (Tachimori et al, 2009) or the nationwide registry (5%) (The Japan Esophageal Society). Second, definitive CRTx for resectable EC has the merit of preserving the esophagus, though it may increase late toxicity such as pericardial or pleural effusion Kumekawa et al, 2006). Pericardial and pleural effusion developed in nearly 20% of complete response patients, leading to 10-12% of treatment-related deaths Kumekawa et al, 2006).…”

“…Second, definitive CRTx for resectable EC has the merit of preserving the esophagus, though it may increase late toxicity such as pericardial or pleural effusion Kumekawa et al, 2006). Pericardial and pleural effusion developed in nearly 20% of complete response patients, leading to 10-12% of treatment-related deaths Kumekawa et al, 2006). Even in the earlier stage squamous cell cancer, definitive CRTx-related mortality was observed in 8% of complete response patients (Minashi et al, 2006).…”